On May 19, 2025, Regeneron Pharmaceuticals announced it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co., a leading human genetics and biotechnology company.

Regeneron intends to acquire 23andMe’s Personal Genome Service^® (PGS), Total Health and Research Services business lines, together with its Biobank and associated assets, for $256 million and for 23andMe to continue all consumer genome services uninterrupted.

Subject to bankruptcy court and regulatory approvals and other customary closing conditions, the transaction is expected to close in the third quarter of 2025.

Regeneron intends to ensure compliance with 23andMe’s consumer privacy policies and applicable laws with respect to the treatment of customer data. As the successful bidder, Regeneron is prepared to detail the intended use of customer data and the privacy programs and security controls in place for review by a court-appointed, independent Customer Privacy Ombudsman and other interested parties.

23andMe will be operated as a wholly owned direct or indirect subsidiary of Regeneron Pharmaceuticals,
and continue operations as a personal genomics service. Regeneron’s purchase does not include 23andMe’s Lemonaid Health business.